UBS Sees $15 Billion Sales Potential for Eli Lilly's (LLY) Obesity Treatment Orforglipron

Eli Lilly & Company (NYSE:LLY) ranks among the most active stocks to buy according to Wall Street analysts. Following favorable Phase 3 trial findings for Eli Lilly & Company (NYSE:LLY)’s obesity treatment, UBS reaffirmed its Buy rating and $895 price target on the company on August 27. The pharmaceutical company revealed topline results from its ATTAIN-2 trial examining orforglipron in individuals with obesity and type 2 diabetes.

According to UBS, the data is “a clear positive,” with orforglipron demonstrating efficacy in the same patient population that is comparable to rival Novo Nordisk’s Wegovy. According to the bank, the findings support the clinical profile of orforglipron in the treatment of obesity and point to a “more optimistic commercial outlook” than investors had anticipated in the wake of the previous ATTAIN-1 results.

Based on current market consensus, UBS retains a peak sales forecast of $15 billion for the medication while it awaits full data presentation at the European Association for the Study of Diabetes (EASD) for comprehensive safety and efficacy information.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.